Development Bank of Japan Inc. (DBJ) has entered into an investment agreement with 4BIO Ventures III LP, a biotech venture fund managed by 4BIO Partners LLP.
4BIO Partners LLP focuses its investments on early-stage biotech ventures that use innovative modalities to develop treatments leading to solutions for unmet medical needs. Headquartered in London and with a global network spanning North America, Europe, Japan and other parts of Asia, the firm was founded in 2014 and has since invested in biotech ventures developing new drug discovery modalities involving cell and gene therapy, RNA-based medicine, targeted therapies, and the microbiome. Its team comprises leading-edge researchers from academia and people with extensive investment experience in the life science field. These experts identify the best investment opportunities and provide hands-on support to investees.
By linking Japan's startup ecosystem with its counterparts overseas, DBJ and its subsidiary, DBJ Capital K.K., work to support the creation of new, potentially life-transforming medical treatments for all patients. Our investment in 4BIO Ventures III LP will bring us in touch with the latest overseas advancements in the field, while collaboration with 4BIO Partners LLP will help us in our efforts to revitalize Japan's life science ecosystem by supporting the expansion of Japanese biotech ventures overseas and promoting business development by Japanese firms.
DBJ will pass on the knowledge gained through this project for the development of Japan's life science ecosystem and the benefit of people at home and around the world.
Inquiries:
Healthcare Industry Office, Corporate Finance Department, Division 6
Telephone: +81-3-3244-1730